Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
US Army
Merck
UBS
Dow
US Department of Justice
Harvard Business School
Baxter
Daiichi Sankyo

Generated: June 24, 2018

DrugPatentWatch Database Preview

DORIBAX Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Doribax, and when can generic versions of Doribax launch?

Doribax is a drug marketed by Shionogi Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has sixteen patent family members in fourteen countries.

The generic ingredient in DORIBAX is doripenem. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the doripenem profile page.
Drug patent expirations by year for DORIBAX
Pharmacology for DORIBAX
Ingredient-typeCarbapenems
Drug ClassPenem Antibacterial
Synonyms for DORIBAX
(+)-(4R,5S,6S)-6-((1R)-1-Hydroxyethyl)-4-methyl-7-oxo-3-(((3S,5S)-5-((sulfamoylamino)methyl)-3-pyrrolidinyl)thio)-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid
(+)-(4R,5S,6S)-6-[(1R)-1-HYDRO-XYETHYL]-4-METHYL-7-OXO-3-[[(3S,5S)-5-[(SULFAMOYLAMINO)-METHYL]-3-PYRROLIDINYL]THIO]-1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID MONOHYDRATE
(4R,5S,6S)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-3-(((3S,5S)-5-((sulfamoylamino)methyl)pyrrolidin-3-yl)thio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-6-((R)-1-hydroxyethyl)-4-Methyl-7-oxo-3-((3S,5S)-5-((sulfaMoylaMino)Methyl)pyrrolidin-3-ylthio)-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-{[(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl]sulfanyl}-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
016D813
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3S,5S)-5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-((1R)-1-hydroxyethyl)-4-methyl-7-oxo-, (4R,5S,6S)-
1-Azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((aminosulfonyl)amino)methyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-(3(3S*,5S*),4alpha,5beta,6beta(R*)))-
148016-81-3
364622-82-2
ABP000725
AC1L2JMJ
AJ-47442
AK326124
AKOS015918362
AM84446
AN-7043
AVAACINZEOAHHE-VFZPANTDSA-N
BCP9000623
BCPP000252
BDBM50088382
BHV525JOBH
C-23919
CAS-148016-81-3
CC-27371
CHEBI:135928
CHEMBL1721631
CHEMBL491571
CS-2075
D03895
D03QWT
D5249
DB06211
Doribax (TN)
Doripenem
Doripenem (USAN/INN)
Doripenem [USAN:INN]
Doripenem Hydrate/Doribax/S-4661/Finibax/
Doripenem monohydrate
DR002580
DRPM
DSSTox_CID_26678
DSSTox_GSID_46678
DSSTox_RID_81814
DTXSID2046678
Finibax
FT-0081127
FT-0651042
HE111624
HY-B0187
I14-8431
MFCD02092739
MFCD09749887
MolPort-006-069-366
NCGC00167510-01
NCGC00167510-02
RL01870
S 4661
S-4661
SCHEMBL37471
SR-01000872589
SR-01000872589-1
ST2401965
Tox21_112508
Tox21_112508_1
UNII-BHV525JOBH
ZINC3922770

US Patents and Regulatory Information for DORIBAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-002 Oct 5, 2010 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-001 Oct 12, 2007 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for DORIBAX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-002 Oct 5, 2010 ➤ Try a Free Trial ➤ Try a Free Trial
Shionogi Inc DORIBAX doripenem INJECTABLE;IV (INFUSION) 022106-001 Oct 12, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for DORIBAX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 250 mg/vial and 500 mg/vial ➤ Subscribe 2011-10-11

Non-Orange Book US Patents for DORIBAX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,221,823 Crystal form of pyrrolidylthiocarbapenem derivative ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for DORIBAX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3 Finland ➤ Try a Free Trial
00374 Netherlands ➤ Try a Free Trial PRODUCT NAME: DORIPENEM; REGISTRATION NO/DATE: EU/1/08/467/001 20080725
0528678/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: DORIPENEMUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58667 19.10.2009
09/002 Ireland ➤ Try a Free Trial PRODUCT NAME: DORIPENEM.; REGISTRATION NO/DATE: EU/1/08/467/001 20080725
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
QuintilesIMS
Argus Health
Mallinckrodt
Express Scripts
Merck
Cantor Fitzgerald
Moodys
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.